Skip to main content
Premium Trial:

Request an Annual Quote

Won't Cover or Administer

Six health insurance companies say they won't cover Biogen's Alzheimer's disease drug, calling it experimental even though it was approved last month by the US Food and Drug Administration, the Boston Globe reports. Additionally, the New York Times writes that at least two major medical centers say they will not administer the drug either.

FDA's approval of aducanumab, or Biogen's Aduhelm, last month was controversial. An FDA advisory panel determined last November that there was not enough data indicating the drug slowed cognitive decline among Alzheimer's disease patients, and the agency's subsequent approval — even though the agency typically follows the advice of its advisors — led a handful of panel members to resign. Additionally, the acting commissioner of the agency, Janet Woodcock, has sought an independent investigation of the drug's approval.

Now, according to the Globe, six Blue Cross and Blue Shield affiliates — in Florida, New York, Michigan, North Carolina, and Pennsylvania — say they will not cover the drug because it is "investigational" or "experimental" or because "a clinical benefit has not been established."

Tufts Medical Center Institute for Clinical Research and Health Policy Studies' James Chambers tells the Globe this is unprecedented for an approved drug.

At the same time, the Times reports that the Cleveland Clinic and the Mount Sinai Health System in New York have also said they will not administer the drug. "Based on the current data regarding its safety and efficacy, we have decided not to carry aducanumab at this time," the Cleveland Clinic says in a statement, according to the Times.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.